Publications by authors named "Olivier Bayle"

10 Publications

  • Page 1 of 1

Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results.

World J Clin Cases 2021 Jun;9(18):4559-4572

Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, Marseille 13008, France.

Background: Careful selection of hepatocellular carcinoma (HCC) patients prior to chemoembolization treatment is a daily reality, and is even more necessary with new available therapeutic options in HCC.

Aim: To propose two new models to better stratify patients and maximize clinical benefit: "6 and 12" and "pre/post-TACE-predict" (TACE, transarterial chemoembolization).

Methods: We evaluated and compared their performance in predicting overall survival with other systems {Barcelona Clinic Liver Cancer (BCLC), Albumin-Bilirubin (ALBI) and NIACE [Number of tumor(s), Infiltrative HCC, alpha-fetoprotein, Child-Pugh (CP), and performance status]} in two HCC French cohorts of different stages enrolled between 2010 and 2018.

Results: The cohorts included 324 patients classified as BCLC stages A/B (cohort 1) and 137 patients classified as BCLC stages B/C (cohort 2). The majority of the patients had cirrhosis with preserved liver function. "Pre-TACE-predict" and "6 and 12" models identified three distinct categories of patients exhibiting different prognosis in cohort 1. However, their prognostic value was no better than the BCLC system or NIACE score. Liver function based on CP and ALBI grades significantly impacted patient survival. Conversely, the "post-TACE-predict" model had a higher predictive value than other models. The stratification ability as well as predictive performance of these new models in an intermediate/advanced stage population was less efficient (cohort 2).

Conclusion: The newly proposed "Pre-TACE-predict" and "6 and 12" models offer an interesting stratification into three categories in a recommended TACE population, as they identify poor candidates, those with partial control and durable response. The models' contribution was reduced in a population with advanced stage HCCs.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v9.i18.4559DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223847PMC
June 2021

Efficacy of Chest CT for COVID-19 Pneumonia Diagnosis in France.

Radiology 2021 02 1;298(2):E81-E87. Epub 2020 Sep 1.

From the University Hospital Centre Poitiers, Radiology, 2 rue de la Milétrie, 86000 Poitiers, Vienne, France (G. Herpe.); Laboratoire de Mathématiques et Applications Université de Poitiers, DACTIM-MIS TEAM, Chasseneuil, Nouvelle Aquitaine, France (G. Herpe.); University Hospital of Rennes, Radiology, Rennes, Ille-et-Vilaine, France (M. Lederlin.); University of Rennes, Rennes, Ille-et-Vilaine, France (M. Lederlin.); Université de Poitiers Laboratoire de Mathématiques et Applications, DACTIM-MIS, Chasseneuil, Nouvelle Aquitaine, France (M.N.); University Hospital Centre Poitiers, DACTIM-MIS, Poitiers, France (M.N.); Nouvel Hôpital Civil, Radiology, Strasbourg, Alsace, France (M.O.); APHM, Radiology, Marseille, PACA, France (K.C.); AMU, Marseille, PACA, France (K.C.); Beaujon Hospital Department of Medical Imaging, Radiology, Clichy, France (J.G.); Beaujon University Hospitals Paris Nord Val de Seine, Radiology, Clichy, Hauts-de-Seine, France (V.V.); CHU Nîmes, Nîmes, Gard, France (C.A.F.); Hôpital Saint-Louis, Radiology, Paris, Île-de-France, France (C.D.M.M.); Université de Paris, INSERM U1149-Center for Research on Inflammation, Paris, Île-de-France, France (C.D.M.M.); Centre Hospitalier Universitaire de Nice Hôpital Pasteur, Radiology, Nice, Alpes Maritimes, France (V.F.); Centre Hospitalier Annecy Genevois, Radiology, Epagny Metz-Tessy, Auvergne-Rhône-Alpes, France (M. Ludwig.); CHU Nice, Radiology, Nice, PACA, France (L.M.); European Hospital Group Georges-Pompidou, Radiology, Paris, Île-de-France, France (I.F.); Université de la Méditérranée, Faculté de Médecine de Marseille, Centre de Résonance Magnétique Biologique et Médicale (CRMBM), UMR CNRS no. 6612, Marseille, BdR, France (A.R.R.J.); Centre Hospitalo Universitaire la Timone, Service de Radiologie Cardiovasculaire, Marseille, France (A.R.R.J.); Centre Hospitalier de la Côte Basque, Bayonne, Nouvelle Aquitaine, France (P.A.); CHRU de Nancy, Radiology, Nancy, Grand Est, France (I.P.); HIA Legouest, Service d'Imagerie Médicale, Metz, France (A.G.); CHU Nancy, Service D'imagerie Guilloz, Nancy, France (A.G.); Hôpital Saint-Joseph, Radiology, Marseille, PACA, France (O.B.); Clinique Emilie de Vialar, IMEV, Radiologie, Rhône, France (A.C.); CH Douai, NORD, Loffre, France (M.M.S.); University Hospital Centre Poitiers, Poitiers, Vienne, France (C.T.); CHRDS, Neuilly-sur-Seine, Neuilly-sur-Seine, France (G. Henry.);, Île de France, France (V.B.); Hôpital d'Instruction des Armées Begin, Radiology, Saint Mande, Île-de-France, France (T.L.T.); Hôpital d'Instruction des Armées Percy, Radiology, Clamart, Île-de-France, France (T.L.T.); CHU Limoges, Radiology, Limoges, Nouvelle Aquitaine, France (M.S.G.); CHU Dupuytren, Radiologie, Limoges, Haute-Vienne, France (P.G.); Military Teaching Hospital Clermont-Tonnerre, Radiology, Brest, Bretagne, France (M.G.); Hôpital Argenteuil, Argenteuil, Île-de-France, France (E.B.); Centre Hospitalier Pierre-le-Damany Lannion Trestel, Kergomar, Lannion, Bretagne, France (C.M.); Institut Bergonie, Bordeaux, Nouvelle Aquitaine, France (B.L.); CH Douai, Radiology, Douai, Nord, France (A.K.); Centre Hospitalier de Vienne Lucien Hussel, Medical Imaging, Vienne, Aura, France (H.K.); Hôpital d'Instruction des Armées Laveran, Radiology, Marseille, Bouches-du-Rhône, France (F.D.); CHU Tivoli, La Louvière, Wallonie, Belgium (B.D.); CHU Poitiers, Clinical Investigation Center CIC1402, Poitiers, Vienne, France (P.J.S.); CHU Poitiers, Radiology, Poitiers, Poitou-Charentes, France (R.G.); La Timone Hospital, Radiology, Marseille, BdR, France (J.M.B.); University Hospital Center of Nîmes, Radiology, Nîmes, Gard, France (J.P.B.); Université de Poitiers, Faculté de Médecine et de Pharmacie, Poitiers, France, France (J.P.T.); and CHU de Poitiers, Service de Radiologie, Poitiers, France, France (J.P.T.) .

Background The role and performance of chest CT in the diagnosis of the coronavirus disease 2019 (COVID-19) pandemic remains under active investigation. Purpose To evaluate the French national experience using chest CT for COVID-19, results of chest CT and reverse transcription polymerase chain reaction (RT-PCR) assays were compared together and with the final discharge diagnosis used as the reference standard. Materials and Methods A structured CT scan survey (NCT04339686) was sent to 26 hospital radiology departments in France between March 2, 2020, and April 24, 2020. These dates correspond to the peak of the national COVID-19 epidemic. Radiology departments were selected to reflect the estimated geographic prevalence heterogeneities of the epidemic. All symptomatic patients suspected of having COVID-19 pneumonia who underwent both initial chest CT and at least one RT-PCR test within 48 hours were included. The final discharge diagnosis, based on multiparametric items, was recorded. Data for each center were prospectively collected and gathered each week. Test efficacy was determined by using the Mann-Whitney test, Student test, χ test, and Pearson correlation coefficient. < .05 indicated a significant difference. Results Twenty-six of 26 hospital radiology departments responded to the survey, with 7500 patients entered; 2652 did not have RT-PCR test results or had unknown or excess delay between the RT-PCR test and CT. After exclusions, 4824 patients (mean age, 64 years ± 19 [standard deviation], 2669 male) were included. With final diagnosis as the reference, 2564 of the 4824 patients had COVID-19 (53%). Sensitivity, specificity, negative predictive value, and positive predictive value of chest CT in the diagnosis of COVID-19 were 2319 of 2564 (90%; 95% CI: 89, 91), 2056 of 2260 (91%; 95% CI: 91, 92), 2056 of 2300 (89%; 95% CI: 87, 90), and 2319 of 2524 (92%; 95% CI: 91, 93), respectively. There was no significant difference for chest CT efficacy among the 26 geographically separate sites, each with varying amounts of disease prevalence. Conclusion Use of chest CT for the initial diagnosis and triage of patients suspected of having coronavirus disease 2019 was successful. © RSNA, 2021
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2020202568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465292PMC
February 2021

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.

Eur J Gastroenterol Hepatol 2019 Nov;31(11):1414-1423

Department of Gastroenterology and Hepatology.

Background: Conventional transarterial chemoembolization (cTACE) with lipiodol is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable for curative treatment. Additional tumor parameters such as HCC macroscopic appearance based on imaging might be helpful for transarterial chemoembolization prognostication and management.

Patients And Methods: A total of 405 patients with HCC who underwent cTACE between 2008 and 2016 from a real-life multicenter French cohort were retrospectively reviewed. Tumors were classified into two macroscopic types according to HCC gross appearance on imaging: nodular versus non-nodular. The study population was stratified into two groups: derivation and validation cohorts. Independent prognostic factors of survival based on multivariate cox regression models were determined and then assessed in the validation set. Thereafter, time to progression (TTP) and radiological response rate were investigated for each prognostic factors of survival.

Results: Median overall survival (OS) was 35 months for Barcelona Clinic Liver Cancer (BCLC) stage A, 22 months for BCLC stage B and 12 months for BCLC stage C patients (P < 0.0001). The corresponding TTP for these patients was 12 (7-17) months, 5 (3-6) months and 1.2 (1.2-3) months (P < 0.0001). Multivariate analysis revealed that tumors size and number, non-nodular type, alpha-fetoprotein, aspartate aminotransferase serum levels and impairment of performance status-1 were independent predictors of survival among the study groups. Non-nodular type was the most powerful factor that influences OS, TTP and radiological response rate for the recommended transarterial chemoembolization candidates. TTP was consistent with OS within each stage.

Conclusion: HCC macroscopic appearance on imaging is a determinant predictor of outcome after cTACE in a real-life multicenter cohort.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001420DOI Listing
November 2019

Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.

Eur J Gastroenterol Hepatol 2018 Apr;30(4):368-375

Departments of Hepato-Gastroenterology.

Background: Direct-acting antivirals (DAAs) therapy against hepatitis C viral (HCV) infection has markedly improved the sustained viral response. However, recent studies have suggested an unsuspected high rate of hepatocellular carcinoma (HCC) recurrence.

Patients And Methods: A retrospective case-control study was carried out to investigate the impact of DAAs on tumor recurrence in patients with complete response to HCC treatment within our HCV-related cirrhosis cohort. Patients who received [group 1 (G1), n=22] or not [group 2 (G2), n=49] a DAAs therapy were matched 1 : 2 for age, sex, liver function, HCC stage, and treatment.

Results: Initial HCC were mostly Barcelona Clinic Liver Cancer stage A (95% G1, 94% G2). Sustained viral response with DAAs was achieved in 86% of patients. After a similar median overall follow-up time with similar radiologic surveillance after HCC treatment, 41% of patients developed radiologic tumor recurrence in G1 versus 35% of patients in G2 (P=0.7904). There was no significant difference in time to progression between the two groups [12 (9-16) months G1 vs. 14 (8-21) months G2, P=0.7688], or Barcelona Clinic Liver Cancer stage at recurrence. However, the interval between HCC treatment and antiviral therapy was significantly different among DAAs patients with recurrence and those without recurrence [7.0 (2.5-9.0) months vs. 36.0 (9.0-58.0) months, P=0.0235, respectively].

Conclusion: In our case-control study, HCV therapy with DAAs does not accelerate or prevent early HCC recurrence compared with untreated patients. The rate of recurrence, time to progression, and HCC pattern are similar. Early DAAs treatment (<12 months) after HCC cure should be discouraged considering the HCC recurrence rate during this period.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001082DOI Listing
April 2018

Habitability on Early Mars and the Search for Biosignatures with the ExoMars Rover.

Astrobiology 2017 Jul;17(6-7):471-510

The second ExoMars mission will be launched in 2020 to target an ancient location interpreted to have strong potential for past habitability and for preserving physical and chemical biosignatures (as well as abiotic/prebiotic organics). The mission will deliver a lander with instruments for atmospheric and geophysical investigations and a rover tasked with searching for signs of extinct life. The ExoMars rover will be equipped with a drill to collect material from outcrops and at depth down to 2 m. This subsurface sampling capability will provide the best chance yet to gain access to chemical biosignatures. Using the powerful Pasteur payload instruments, the ExoMars science team will conduct a holistic search for traces of life and seek corroborating geological context information. Key Words: Biosignatures-ExoMars-Landing sites-Mars rover-Search for life. Astrobiology 17, 471-510.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1089/ast.2016.1533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685153PMC
July 2017

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.

World J Gastroenterol 2017 Apr;23(14):2545-2555

Xavier Adhoute, Hervé Perrier, Paul Castellani, Marc Bourlière, Department of Hepato-Gastroenterology, Hôpital Saint-Joseph Marseille, 13008 Marseille, France.

Aim: To compare the performances of the Barcelona clinic liver cancer (BCLC) nomogram and others systems (BCLC, HKLC, CLIP, NIACE) for survival prediction in a large hepatocellular carcinoma (HCC) French cohort.

Methods: Data were collected retrospectively from 01/2007 to 12/2013 in five French centers. Newly diagnosed HCC patients were analyzed. The discriminatory ability, homogeneity ability, prognostic stratification ability Akaike information criterion (AIC) and C-index were compared among scoring systems.

Results: The cohort included 1102 patients, mostly men, median age 68 [60-74] years with cirrhosis (81%), child-Pugh A (73%), alcohol-related (41%), HCV-related (27%). HCC were multinodular (59%) and vascular invasion was present in 41% of cases. At time of HCC diagnosis BCLC stages were A (17%), B (16%), C (60%) and D (7%). First line HCC treatment was curative in 23.5%, palliative in 59.5%, BSC in 17% of our population. Median OS was 10.8 mo [4.9-28.0]. Each system distinguished different survival prognosis groups ( < 0.0001). The nomogram had the highest discriminatory ability, the highest C-index value. NIACE score had the lowest AIC value. The nomogram distinguished sixteen different prognosis groups. By classifying unifocal large HCC into tumor burden 1, the nomogram was less powerful.

Conclusion: In this French cohort, the BCLC nomogram and the NIACE score provided the best prognostic information, but the NIACE could even help treatment strategies.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v23.i14.2545DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394518PMC
April 2017

NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.

Eur J Gastroenterol Hepatol 2017 Jun;29(6):706-715

aDepartment of Hepato-Gastroenterology bDepartment of Hepatobiliary Surgery cDepartment of Radiology, Hôpital Saint-Joseph dAlphaBio Laboratory eDepartment of Hepato-Gastroenterology and Digestive Oncology, Institut Paoli-Calmette fDepartment of Hepatobiliary Surgery, Centre Hospitalo-Universitaire Timone, Marseille gDepartment of Hepato-Gastroenterology, Centre Hospitalo-Universitaire de Nancy hINSERM U954, Université de Lorraine, CHU de Nancy, Vandoeuvre les Nancy, France.

Background And Aims: Hepatocellular carcinoma (HCC) prognostic scores could be useful in addition to the Barcelona Clinic Liver Cancer (BCLC) system to clarify patient prognosis and guide treatment decision. The NIACE (tumor Nodularity, Infiltrative nature of the tumor, serum Alpha-fetoprotein level, Child-Pugh stage, ECOG performance status) score distinguishes different prognosis groups among BCLC A, B, and C HCC patients. Our aims are to evaluate the NIACE score and its additive value in two HCC cohorts treated either by surgery or by chemoembolization, and then according to the BCLC recommendations.

Patients And Methods: This was a retrospective multicenter study with two BCLC A, B, and C HCC cohorts treated either by surgery (n=207) or by chemoembolization (n=168) carried out between 2008 and 2013. We studied survival time according to the baseline NIACE score and compared it with the Cancer of the Liver Italian Program score and the BCLC system.

Results: The NIACE score differentiates between subgroups of patients with different prognosis within each BCLC class. Among BCLC A patients treated by surgery and BCLC B patients treated by chemoembolization, the NIACE score differentiates between two subgroups with a significant difference in survival time: 68 (55-81) months versus 35 (21-56) months (P=0.0004) and 20 (17-24) months versus 13 (7-17) months (P=0.0008), respectively. Among those subgroups, the NIACE score has a significantly better prognostic value than the BCLC system or the Cancer of the Liver Italian Program score.

Conclusion: In this study, among HCC patients treated according to the BCLC recommendations, the NIACE score predicts more accurately than any other system the survival time.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000000852DOI Listing
June 2017

Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.

Eur J Gastroenterol Hepatol 2016 Apr;28(4):433-40

Departments of aHepato-Gastroenterology bHepatobiliary Surgery cRadiology, Hôpital Saint-Joseph dAlphaBio Laboratory eDepartment of Hepato-Gastroenterology and Digestive Oncology, Institut Paoli-Calmette, Marseille fDepartment of Hepato-Gastroenterology, Centre Hospitalo-Universitaire, Saint-André Bordeaux, Bordeaux gDepartment of Hepato-Gastroenterology and Digestive Oncology, Centre Eugène Marquis, Rennes hDepartment of Hepato-Gastroenterology iINSERM U954, Université de Lorraine, CHU de Nancy, Vandoeuvre les Nancy, France.

Background: Advanced hepatocellular carcinoma (HCC) includes a wide spectrum of tumors and patients' prognosis after treatment is highly variable. Moreover, therapeutic options based on the Barcelona Clinic Liver Cancer (BCLC) staging system algorithm are restricted to one systemic therapy.

Aim Of The Study: To refine the stratification among BCLC C HCC patients by establishing a new simple prognostic score.

Patients And Methods: A regression model based on a BCLC stage C population and validated with an external cohort of BCLC C HCC patients defined the score. It was therefore validated among three external cohorts of BCLC C HCC patients treated with sorafenib.

Results: Five variables had independent prognostic values: the number of nodules, the infiltrating nature of the HCC, α-fetoprotein serum level, Child-Pugh score, and Eastern Cooperative Oncology Group Performance Status grade. They were integrated into a new score named NIACE ranging from 0 to 7, well correlated with survival. With the use of one threshold value, this score enables defining of two populations with different survivals among BCLC C patients and specifically among those treated with sorafenib.

Conclusion: The NIACE score defines different prognostic subgroups after palliative treatment of HCC. It could be an additional tool for BCLC C HCC before inclusion in clinical trials or for the management of patients. These results must be validated in a prospective study.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000000558DOI Listing
April 2016

Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.

J Hepatol 2015 Apr 21;62(4):855-62. Epub 2014 Nov 21.

Department of Hepato-Gastroenterology, Hôpital Saint-Joseph Marseille, France. Electronic address:

Background & Aims: Transarterial chemoembolization (TACE) is the standard of care for intermediate stage hepatocellular carcinoma (HCC) and it is the most commonly used treatment for HCC worldwide. However, no prognostic indices, designed to select appropriate candidates for repeat conventional TACE, have been incorporated in the guidelines.

Methods: From January 2007 to April 2012, 139 consecutive HCC patients, mainly with an alcohol- or viral-induced disease, were treated with TACE. Using a regression model on the prognostic variables of our population, we determined a score designed to help for repeat TACE and we validated it in two cohorts. We also compared it to the ART score.

Results: In the multivariate analysis, four prognostic factors were associated with overall survival: BCLC and AFP (>200 ng/ml) at baseline, increase in Child-Pugh score by ⩾2 from baseline, and absence of radiological response. These factors were included in a score (ABCR, ranging from -3 to +6), which correlates with survival and identifies three groups. The ABCR score was validated in two different cohorts of 178 patients and proofed to perform better than the ART score in distinguishing between patients' prognosis.

Conclusions: The ABCR score is a simple and clinically relevant index, summing four prognostic variables endorsed in HCC. An ABCR score ⩾4 prior to the second TACE identifies patients with dismal prognosis who may not benefit from further TACE sessions.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2014.11.014DOI Listing
April 2015
-->